neuroQWERTY: a Transparent Patient-centered Outcome Method to Quantify Parkinsonian Motor Signs for Drug Trials

Inclusion criteria

• Participants between 18 years and 70 years (older subjects will be deemed eligible on an individual basis after review by the study team).
• Parkinson's disease (PD) diagnosis according to the United Kingdom Brain Bank Criteria.
• PD patients without cognitive or psychiatric disturbances, as measured by the baseline assessment.
• Prescription of symptomatic therapy with L-Dopa or dopamine agonists based on functional impairment attributed to PD. This will be based on the participant's physician criteria based on:

• Involvement of the dominant hand and/or upper limbs.
• Employed patients which the disease impairs their ability to work.
• Daily computer use > 30 minutes

Exclusion criteria

• Mild cognitive impairment or dementia.
• Psychiatric symptoms
• Expected or current use of sedative medication (benzodiazepines, opiates, antihistaminergic drugs).
• Neuroleptic use.
• History of parkinsonism for the controls.
• Severe osteo-articular problems with upper limb functional limitation (amputations, severe osteo-arthritis).
• Alcohol risk use (>40 gr/day or 4 standard drinks for male / >24gr/day or 2 standard drinks for female).
• Narcolepsy or other sleep disorder producing hypersomnia (obstructive apnea, acute confusional states).
• Any other life- threatening condition (advanced cancer, severe hepatic or renal insufficiencies.